Table 1 The clinicopathologic features of carcinoma cases (n = 48)

Presence of polyps

1 (2.1%)

Adjacent adenoma

4 (8.3%)

Multiple tumors

2 (4.2%)

Gross description

Infiltrating

15 (31.3%)

Fungating

24 (50%)

Ulcerating

9 (18.8%)

Gross perforation

9 (18.8%)

Grade

Low & intermediate

39 (81.3%)

High

9 (18.8%)

T stage

T2

7 (14.6%)

T3

31 (64.6%)

T4

10 (20.8%)

N stage

N0

28 (58.3%)

N1

12 (25.0%)

N2

8 (16.7%)

M stage

M0

36 (75%)

M1

12 (25%)

Modified Duke’s staging

B

25 (52.1%)

C

18 (37.5%)

D

5 (10.4%)

Combined Dukes

B, C

43 (89.6%)

D

5 (10.4%)

Necrosis

13 (27.1%)

Apoptosis (n = 21)

Mean ± SD

25.6 ± 22.1

Median (min.–max.)

20 (2–90)

Mitosis

Mean ± SD

9.4 ± 6.4

Median (min.–max.)

8.5 (1–28)

Vascular invasion

15 (31.3%)

Perineural invasion

11 (22.9%)

Lymph node harvest

Mean ± SD

14.6 ± 9.2

Median (min.–max.)

12.5 (2–45)

Lymph node metastasis [N_ combined]

N0

41 (85.4%)

N1, 2

7 (14.6%)

Type of tumor/variant (n = 47)

Signet

3 (6.4%)

Adenocarcinoma

37 (78.7%)

Mucinous

3 (6.4%)

Adenocarcinoma with mucinous differentiation

4 (8.5%)

Inflammatory response

40 (85.1%)

Tumor. budding

Low (< 5)

22 (45.8%)

Intermediate (5–9)

20 (41.7%)

High (≥ 10)

6 (12.5%)

Recurrence

9 (18.8%)

Death

24 (50.0%)

Overall survival (n = 45)

Mean ± SD

18.76 ±11.98

Median (min.–max.)

17 (1-50)